{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:47:19Z","timestamp":1769827639926,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":95,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100706","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T12:24:28Z","timestamp":1681215868000},"page":"100706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A low risk of recurrence after breast-conserving surgery for DCIS: A single-institution experience"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-9275","authenticated-orcid":false,"given":"Sara","family":"van Bekkum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Drukker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"van Rosmalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian B.E.","family":"Menke-Pluijmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter J.","family":"Westenend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100706_bib0001","unstructured":"Dutch breast cancer guideline (2021). Available at: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker."},{"key":"10.1016\/j.ctarc.2023.100706_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.breast.2018.07.007","article-title":"Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: a multi-center study and population-based analysis","volume":"42","author":"Jobsen","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ctarc.2023.100706_bib0003","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/jca.2.232","article-title":"Biological markers in DCIS and risk of breast recurrence: a systematic review","volume":"2","author":"Lari","year":"2011","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100706_bib0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"van Seijen","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100706_bib0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.ctarc.2023.100706_bib0006","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","article-title":"Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853 - A study by the EORTC breast cancer cooperative group an","volume":"24","author":"Bijker","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2023.100706_bib0007","article-title":"Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis","volume":"85","author":"Boyages","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2023.100706_bib0008","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/his.12796","article-title":"Ductal carcinoma in situ - update on risk assessment and management","volume":"68","author":"Pang","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2023.100706_bib0009","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/bjc.2012.41","article-title":"HER2\/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ","volume":"106","author":"Rakovitch","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100706_bib0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1470-2045(06)70861-0","article-title":"Heterogeneity of ductal carcinoma in situ and its effects on management","volume":"7","author":"Mokbel","year":"2006","journal-title":"Lancet Oncol."},{"issue":"9114","key":"10.1016\/j.ctarc.2023.100706_bib0011","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","author":"Abe","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100706_bib0012","doi-asserted-by":"crossref","DOI":"10.1159\/000431029","article-title":"Targeted therapies in HER2-positive breast cancer - a systematic review","volume":"10","author":"Schramm","year":"2015","journal-title":"Breast Care"},{"key":"10.1016\/j.ctarc.2023.100706_bib0013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","article-title":"Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2023.100706_bib0014","doi-asserted-by":"crossref","DOI":"10.1080\/13543784.2022.2042252","article-title":"Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.ctarc.2023.100706_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/13543784.2022.2008354","article-title":"Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond","volume":"31","author":"Rizzo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"609","key":"10.1016\/j.ctarc.2023.100706_bib0016","first-page":"1","article-title":"Ductal carcinoma in situ of the breast: an update with emphasis on radiological and morphological features as predictive prognostic factors","volume":"12","author":"Salvatorelli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2023.100706_bib0017","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-016-4007-5","article-title":"Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer","volume":"160","author":"Nordenskj\u00f6ld","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2023.100706_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jnci\/djq101","article-title":"Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis","volume":"102","author":"Kerlikowske","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ctarc.2023.100706_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119565","article-title":"Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer: a retrospective study","volume":"10","author":"Tashima","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2023.100706_bib0020","doi-asserted-by":"crossref","DOI":"10.2147\/BCTT.S305440","article-title":"The proper Ki-67 cut-off in hormone responsive breast cancer: a monoinstitutional analysis with long-term follow-up","volume":"13","author":"Lombardi","year":"2021","journal-title":"Breast Cancer Targets Ther."},{"issue":"4","key":"10.1016\/j.ctarc.2023.100706_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2013.153","article-title":"Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information","volume":"27","author":"Feeley","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ctarc.2023.100706_bib0022","unstructured":"Integraal Kankercentrum Nederland (IKNL), NKR cijfers, Selection: survival, invasive breast cancer. 2011-2017, (2023). Available at: https:\/\/iknl.nl\/kankersoorten\/borstkanker\/registratie\/incidentie."},{"key":"10.1016\/j.ctarc.2023.100706_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znab339","article-title":"Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer","author":"Schermers","year":"2021","journal-title":"Br. J. Surg."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100706_bib0024","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-18-0976","article-title":"Predictors of an invasive breast cancer recurrence after DCIS: a Systematic Review and Meta-analyses","volume":"28","author":"Visser","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100706_bib0025","first-page":"1","article-title":"The clinical significance of HER2 expression in DCIS","volume":"40","author":"Akrida","year":"2023","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100706_bib0026","doi-asserted-by":"crossref","DOI":"10.4048\/jbc.2016.19.2.185","article-title":"Predictors of recurrent ductal carcinoma in situ after breast-conserving surgery","volume":"19","author":"Kim","year":"2016","journal-title":"J. Breast Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100706_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2011.09.008","article-title":"Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence","volume":"24","author":"Han","year":"2012","journal-title":"Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2023.100706_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.32362","article-title":"A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast","volume":"146","author":"Van Bockstal","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2023.100706_bib0029","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2023.100706_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.semradonc.2022.01.005","article-title":"Risk assessment in the molecular era","volume":"32","author":"Knowlton","year":"2022","journal-title":"Semin. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100706_bib0031","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-013-2755-z","article-title":"Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43","volume":"142","author":"Siziopikou","year":"2013","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:44Z","timestamp":1762842944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":31,"alternative-id":["S2468294223000278"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100706","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A low risk of recurrence after breast-conserving surgery for DCIS: A single-institution experience","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100706"}}